Department of Blood Transfusion, Fujita Health University Hospital, Toyoake, Aichi, Japan.
Department of Molecular Laboratory Medicine, Fujita Health University School of Medical Sciences, Toyoake, Aichi, Japan.
Transfusion. 2021 Sep;61(9):2782-2787. doi: 10.1111/trf.16557. Epub 2021 Jul 14.
The occurrence of transfusion-transmitted hepatitis B virus (HBV) infection has fallen dramatically due to continuous improvements in pre-transfusion laboratory testing. However, the characteristics of transfusion-transmitted HBV infection caused by individual donor nucleic acid amplification test (ID-NAT)-negative blood products are unclear.
A 76-year-old woman with acute myeloid leukemia was diagnosed with transfusion-transmitted HBV infection after receiving apheresis platelets derived from an ID-NAT-negative blood donation. This case was diagnosed definitively as transfusion-mediated because complete nucleotide homology of a 1556 bp region of the HBV Pol/preS1-preS2-S genes and a 23 bp region of the HBV core promoter/precore between the donor and recipient strains was confirmed by PCR-directed sequencing. The case is uncommon with respect to the unexpectedly prolonged HBV-DNA incubation period of nearly 5 months after transfusion (previously, the longest period observed since the recent implementation of ID-NAT pre-transfusion laboratory testing in Japan was 84 days). Slow-replicating HBV genotype A2 may contribute to the prolonged incubation period; also, the quantity of apheresis platelets delivered in a large volume of plasma, and/or the immune response of the recipient suffering from a hematological neoplasm, may have contributed to establishment of HBV infection in the recipient. This was supported by analysis of three previously documented cases of transfusion-transmitted HBV infection by blood products derived from ID-NAT-negative donations in Japan.
Continuous monitoring of HBV infection for longer periods (>3 months) may be required after transfusion of blood components from an ID-NAT-negative HBV window donation.
由于输血前实验室检测的不断改进,输血传播乙型肝炎病毒(HBV)感染的发生率显著下降。然而,个体供者核酸扩增检测(ID-NAT)阴性血液制品引起的输血传播 HBV 感染的特征尚不清楚。
一名 76 岁女性,患有急性髓系白血病,在接受来自 ID-NAT 阴性献血的单采血小板输注后被诊断为输血传播 HBV 感染。该病例被明确诊断为输血介导的,因为通过 PCR 定向测序证实了供体和受者株之间 HBV Pol/preS1-preS2-S 基因的 1556bp 区域和 HBV 核心启动子/precore 区域的 23bp 区域的 HBV 完全核苷酸同源性。该病例较为罕见,因为输血后 HBV-DNA 的潜伏期长达近 5 个月(此前,自日本最近实施 ID-NAT 输血前实验室检测以来,观察到的最长潜伏期为 84 天)。慢复制 HBV A2 基因型可能导致潜伏期延长;此外,大量血浆中输注的单采血小板,和/或患有血液系统恶性肿瘤的受者的免疫反应,可能有助于受者建立 HBV 感染。这得到了日本三例先前记录的由 ID-NAT 阴性供体血液制品引起的输血传播 HBV 感染病例的分析的支持。
对于来自 ID-NAT 阴性 HBV 窗口期供体的血液成分输注后,可能需要更长时间(>3 个月)持续监测 HBV 感染。